BeiGene's Brukinsa (zanubrutinib) Receives the US FDA's Accelerated Approval for the Treatment of R/R Marginal Zone Lymphoma
Shots:
- The approval is based on 2 trials i.e.- P-II MAGNOLIA & P-I/II BGB-3111-AU-003 trial evaluate Brukinsa (160mg- bid or 320 mg- qd) in 66 & 20 patients with R/R MZL who received at least 1 anti-CD20-based regimen
- Both trial demonstrated ORR (56% & 80%)- CR rate (20% & 20%) based on assessment using CT scan- m-DoR (not yet reached) @median follow-up (8.3 & 31.4mos.)- 85% & 72% of responders still in remission @12mos. Based on assessment prioritizing PET-CT scan- ORR (67%)- CR rate (26%) in MAGNOLIA trial
- The therapy marks 3rd FDA approval in the US & is currently being evaluated in multiple studies globally as a monothx. or in combination with other therapies for multiple B cell malignancies
| Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com